The correlation of IL32 expression with pathological tumor staging in the TCGA cohort was done, and it was raised as T stages increased in PRAD (p = 1.4e-4), KIRC (p = 2.6e-3), PAAD (p = 1.2e-3) (Fig. 2A). This evidence concerns the gene IL32 and prostate adenocarcinoma.